Extended Data Fig. 10: PERK activator CCT020312 potentiates activity of FDA-approved EGFR kinase inhibitors.
From: Identifying transcriptional programs underlying cancer drug response with TraCe-seq
(a–c) Representative qRT-PCR quantification of pro-death genes downstream of ER stress and MAPK target genes in PC9 cells (a, b) and NCI-H1975 cells (c) under the indicated conditions on day 3. Error bars represent s.d., and the centers of the error bars represent the mean of n = 3 biologically dependent technical replicates. These experiments were repeated 2 times (biologically independent) with similar results. (d) Quantification showing EGFRi+CCT020312 combinations were more effective in inducing cell death compared to the single agents using Caspase-Glo3/7 assay system. Error bars represent s.d., and the centers of the error bars represent the mean (n = 3 biologically independent samples). The experiment was repeated 2 times with similar results.
